ResMed stock

RMD · NYSE · USD

Compare ResMed
$241.16Change from previous close: +0.68%Absolute change: +$1.63

Close · November 16, 2026

Price history

−1.45% over the period

1 year: from $244.71 (November 17, 2025) to $241.16 (November 16, 2026), −1.45%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$241.16
October 30, 2026$229.94
September 30, 2026$221.10
August 31, 2026$240.10
July 31, 2026$210.98
June 30, 2026$194.88
May 29, 2026$190.57
April 30, 2026$213.81
March 31, 2026$224.48
February 27, 2026$256.26
January 30, 2026$258.31
December 31, 2025$240.87
November 28, 2025$255.83
November 17, 2025$244.71

At a glance

  • The company

    Develops digital health and cloud-connected medical devices for sleep and breathing health, plus software for residential care providers

  • Latest results

    Quarter to September 30, 2026 · EPS $2.91 (estimate $2.68)

TickerLandia's take on ResMed

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$180.27
52-wk high$277.67

−13.15% from the 52-week high

Analysts · 20 analysts

Average target$264.33+9.61% vs. price

Buy 9 · Hold 10 · Sell 1 · Buy

TickerLandia Fingerprint: ResMed

Compared with similar companies: very high profitability and very high financial strength.

Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

ResMed is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2026), ResMed's P/E today is 23.1, below the median of its last 10 fiscal years (37.7; between 18.7 and 76.1 from 2017 to 2026). ResMed's P/E (trailing 12 months): 21.8, −36% against the median of a group of 9 similar companies (34.2).

P/E compared with its history

Compared with 9 similar companies

ResMed's metrics compared with similar companies
MetricResMedPosition in the groupBand
P/E (trailing 12 months)21.8Low
Forward P/E18.1Middle
Operating margin34.0%High
ROE26.4%High
Debt/equity0.10Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ResMed. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.46B

Latest quarter · Q2 2026

Net income

$383.43M

Latest quarter · Q2 2026

Quarterly net margin

26.2%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$33.69B
P/E
21.8
EPS
$10.98
Volume
836.36K
Daily trading
€309.48M
Dividend yield
1.04%
Last ex-dividend on November 12, 2026

How ResMed is changing

All results
  • Revenue grew 12.1% a year on average over the last 5 years

  • Operating margin rose from 26.8% to 33.4%

  • Profits turn into cash: free cash flow equal to 117% of net income

Returns

ResMed returns with dividends

$1,000 invested in ResMed 5 years ago, on November 16, 2021, would be worth $948 today with dividends reinvested: −5.16% in total, −1.05% per year. On price alone it would be $905 (−9.50%).

PeriodResMedS&P 500$1,000 becomes
1 month+0.91%−3.12%$1,009
6 months+19.45%+2.07%$1,195
Year to date+0.12%+10.46%$1,001
1 year−0.36%+13.33%$996
3 years+66.76%+67.73%$1,668
5 years−5.16%+60.86%$948
10 years+365.29%+247.35%$4,653

Over the last 6 months it has done better than 52% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

ResMed: technical analysis

ResMed shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 18.9% below its all-time closing high ($297.36, September 8, 2021).

Trend
No clear trend
RSI (14 sessions)
54
Between 30 and 70
vs 200-session average
+7.76%

Support and resistance

Price areas where ResMed has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$263.48+9.26%2 touches, last on January 22, 2026
  2. Resistance$258.47+7.18%4 touches, last on October 23, 2026
  3. Resistance$245.43+1.77%2 touches, last on February 12, 2026
  4. Last price$241.16
  5. Support$240.70−0.19%5 touches, last on September 1, 2026
  6. Support$233.95−2.99%3 touches, last on September 15, 2026
  7. Support$222.01−7.94%2 touches, last on November 3, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.50
Volatility (60 sessions, annualised)
31.4%
Largest fall in the last year
−33.75%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

ResMed: seasonality

Average monthly price change over 32 years

+2.5%Jan+0.2%Feb+1.3%Mar+1.4%Apr+0.9%May+3.8%Jun+3.1%Jul+3.1%Aug+1.3%Sep−0.3%Oct+5.6%Nov+1.8%Dec

Over the last 32 years, the strongest month for ResMed has been November: +5.62% on average, positive in 25 years out of 31. The weakest has been October: −0.30% on average, positive in 13 years out of 32.

Show chart data
MonthAverageMedianPositive years
January+2.52%+5.33%22 of 31
February+0.23%+0.35%16 of 31
March+1.27%+1.52%18 of 31
April+1.43%+2.23%17 of 31
May+0.91%+1.75%19 of 31
June+3.81%+3.03%21 of 31
July+3.13%+3.01%24 of 32
August+3.12%+2.39%20 of 32
September+1.26%−0.77%12 of 32
October−0.30%−1.30%13 of 32
November+5.62%+3.40%25 of 31
December+1.81%+1.41%18 of 31

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

ResMed and its competitors

Founded in 1989 and based in San Diego, California, ResMed develops digital health and cloud-connected medical devices, with a focus on sleep apnea. Its sleep recorders, such as ApneaLink Air and NightOwl, are used in sleep clinics, hospitals and at home, while AirView and the myAir application allow remote monitoring of device settings and patient therapy. Through its Residential Care Software segment, the company supplies software to home medical equipment and pharmacy providers, home health and hospice agencies, and skilled nursing and senior living operators, including Brightree, HEALTHCAREfirst, MatrixCare and MEDIFOX DAN.

Headquarters
San Diego, United States
Employees
11,370
Founded
1989
Chief executive
Michael Farrell
ResMed and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ResMedRMD$33.69B34.0%21.8+19.45%
West Pharmaceutical ServicesWST$29.01B22.9%46.7+38.61%
MedlineMDLN$51.94B5.4%89.7+8.01%
Becton, DickinsonBDX$59.39B15.7%43.1+51.77%
SolventumSOLV$15.14B5.9%100.1+20.62%
Baxter InternationalBAX$13.39B7.6%—+48.76%

Same industry or related industries, similar size. Compare ResMed with its competitors · Full profile